NASDAQ:NTEC - Intec Pharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$4.98 +0.16 (+3.32 %)
(As of 10/16/2018 08:00 AM ET)
Previous Close$4.82
Today's Range$4.81 - $5.00
52-Week Range$3.55 - $8.55
Volume33,100 shs
Average Volume145,054 shs
Market Capitalization$185.47 million
P/E Ratio-3.02
Dividend YieldN/A
Beta0.98
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa (AP-CDLD), which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon (AP-ZP) that is in a Phase III clinical trial for the treatment of insomnia, including sleep induction and for enhancing of sleep maintenance; Accordion Pill, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and Accordion Pill platform with Cannabidiol and 9-Tetrahydrocannabinol, (AP-CBD/THC), which is in a Phase I clinical trial for the treatment of various indications, including low back neuropathic pain and fibromyalgia. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd. in March 2004. Intec Pharma Ltd. was founded in 2000 and is based in Jerusalem, Israel.

Receive NTEC News and Ratings via Email

Sign-up to receive the latest news and ratings for NTEC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NTEC
CUSIPN/A
Phone972-2586-4657

Debt

Debt-to-Equity RatioN/A
Current Ratio7.41
Quick Ratio7.41

Price-To-Earnings

Trailing P/E Ratio-3.02
Forward P/E Ratio-3.66
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.26 per share
Price / Book2.20

Profitability

EPS (Most Recent Fiscal Year)($1.65)
Net Income$-29,090,000.00
Net MarginsN/A
Return on Equity-63.39%
Return on Assets-57.89%

Miscellaneous

Employees70
Outstanding Shares32,830,000
Market Cap$185.47 million

Intec Pharma (NASDAQ:NTEC) Frequently Asked Questions

What is Intec Pharma's stock symbol?

Intec Pharma trades on the NASDAQ under the ticker symbol "NTEC."

How were Intec Pharma's earnings last quarter?

Intec Pharma (NASDAQ:NTEC) issued its quarterly earnings results on Wednesday, August, 15th. The biotechnology company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.32) by $0.02. View Intec Pharma's Earnings History.

When is Intec Pharma's next earnings date?

Intec Pharma is scheduled to release their next quarterly earnings announcement on Wednesday, November 21st 2018. View Earnings Estimates for Intec Pharma.

What price target have analysts set for NTEC?

5 brokers have issued 1-year price targets for Intec Pharma's shares. Their forecasts range from $8.50 to $16.00. On average, they anticipate Intec Pharma's share price to reach $12.8750 in the next twelve months. This suggests a possible upside of 158.5% from the stock's current price. View Analyst Price Targets for Intec Pharma.

What is the consensus analysts' recommendation for Intec Pharma?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intec Pharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intec Pharma.

Who are some of Intec Pharma's key competitors?

Who are Intec Pharma's key executives?

Intec Pharma's management team includes the folowing people:
  • Mr. Nir Sassi, Chief Financial Officer (Age 42)
  • Dr. Nadav Navon Ph.D., Chief Operating Officer (Age 49)
  • Mr. Zeev Weiss, Clinical and Bus. Devel. Consultant (Age 56)
  • Mr. Jeffrey A. Meckler, Vice Chairman & CEO (Age 51)
  • Mr. Walt Addison Linscott, Chief Admin. Officer (Age 57)

When did Intec Pharma IPO?

(NTEC) raised $30 million in an IPO on Tuesday, August 4th 2015. The company issued 5,000,000 shares at a price of $6.00 per share. Maxim Group and Roth Capital Partners served as the underwriters for the IPO.

How do I buy shares of Intec Pharma?

Shares of NTEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intec Pharma's stock price today?

One share of NTEC stock can currently be purchased for approximately $4.98.

How big of a company is Intec Pharma?

Intec Pharma has a market capitalization of $185.47 million. The biotechnology company earns $-29,090,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. Intec Pharma employs 70 workers across the globe.

What is Intec Pharma's official website?

The official website for Intec Pharma is http://www.intecpharma.com.

How can I contact Intec Pharma?

Intec Pharma's mailing address is 12 Hartom Street Har Hotzvim, Jerusalem L3, 9777512. The biotechnology company can be reached via phone at 972-2586-4657 or via email at [email protected]


MarketBeat Community Rating for Intec Pharma (NASDAQ NTEC)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  149 (Vote Outperform)
Underperform Votes:  201 (Vote Underperform)
Total Votes:  350
MarketBeat's community ratings are surveys of what our community members think about Intec Pharma and other stocks. Vote "Outperform" if you believe NTEC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTEC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel